Sabine Andereya

Importance to Hirudotherapy

Sabine Andereya's role in modern hirudotherapy is to have provided the second independent randomized confirmation that leech therapy works for osteoarthritis pain — and to have done so in a different joint, with a different patient population, at a different institution from the 2003 Michalsen knee trial. This reproducibility was crucial. The single Charité knee-OA RCT, however well-conducted, was vulnerable to the criticism that a single positive trial in a single indication at a single center could not establish a treatment as effective. Andereya's 2006 Aachen pilot and the 2008 Pain journal follow-up RCT (the latter co-authored with Michalsen but anchored at Aachen) provided the independent confirmation that the field needed. The 2008 Pain trial enrolled 64 women with radiographically-confirmed thumb basal joint OA, randomized to a single application of 4-7 Hirudo verbana leeches over the affected CMC joint versus topical diclofenac twice daily for 28 days. At 8 weeks the leech group showed 53% pain reduction on the VAS (versus 24% in diclofenac); at 6 months the leech group retained 39% pain reduction (versus 12% in diclofenac). Functional measures (DASH score, grip strength) tracked the pain results. The trial's tight inclusion criteria — only women, only radiographically-confirmed CMC arthrosis, only Eaton stage II-III — strengthened its internal validity. Andereya's 2010 12-month follow-up was equally important. She demonstrated that the analgesic effect of a single leech session in CMC arthrosis persisted measurably to one year — an unusual finding in any analgesic intervention and one that supports the proposed mechanism of leech-induced anti-inflammatory and proteolytic modulation of the synovial environment rather than mere local analgesia. ASH considers Andereya the second-most-influential RCT author in modern hirudotherapy after Michalsen, and the indispensable validator of the knee-OA result in a second indication.